Firms to investigate RNAi for Huntington's disease

12/27/2010 | Wall Street Journal, The

Alnylam Pharmaceuticals and Medtronic have teamed up to develop a treatment for Huntington's disease using RNA interference, which can focus on a gene responsible for the production of disease-causing proteins. Medtronic will develop a catheter or a pump that can deliver Alnylam's short, interfering RNA drug directly to the correct area of the brain.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT